{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:32:40Z","timestamp":1793284360716,"version":"4.5.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005565","name":"Janssen Biotech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005565","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006591","name":"FibroGen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006591","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kisupplements.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Supplements"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.kisu.2020.12.003","type":"journal-article","created":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T03:16:10Z","timestamp":1616123770000},"page":"46-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Iron metabolism and management: focus on chronic kidney disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Anil K.","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kisu.2020.12.003_bib1","first-page":"279","article-title":"KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2020.12.003_bib3","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.kisu.2020.12.003_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1681\/ASN.2008020159","article-title":"Timing of onset of CKD-related metabolic complications","volume":"20","author":"Moranne","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2020.12.003_bib7","first-page":"826","article-title":"Prevalence and risk factors of CKD anemia in the United States [abstract SA-PO240]","volume":"30","author":"Davis","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0014-5793(00)01920-7","article-title":"LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity","volume":"480","author":"Krause","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.kisu.2020.12.003_bib9","doi-asserted-by":"crossref","first-page":"7806","DOI":"10.1074\/jbc.M008922200","article-title":"Hepcidin, a urinary antimicrobial peptide synthesized in the liver","volume":"276","author":"Park","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kisu.2020.12.003_bib10","doi-asserted-by":"crossref","first-page":"37597","DOI":"10.1074\/jbc.M205305200","article-title":"The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis","volume":"277","author":"Hunter","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.kisu.2020.12.003_bib11","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1172\/JCI0215686","article-title":"The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation","volume":"110","author":"Nicolas","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kisu.2020.12.003_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semnephrol.2016.02.001","article-title":"Iron balance and the role of hepcidin in chronic kidney disease","volume":"36","author":"Ganz","year":"2016","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/ng1777","article-title":"Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression","volume":"38","author":"Babitt","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.kisu.2020.12.003_bib14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.24359","article-title":"Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice","volume":"54","author":"Corradini","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.kisu.2020.12.003_bib15","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib16","doi-asserted-by":"crossref","first-page":"43ra56","DOI":"10.1126\/scitranslmed.3001127","article-title":"Ferroportin and iron regulation in breast cancer progression and prognosis","volume":"2","author":"Pinnix","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.kisu.2020.12.003_bib17","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1016\/j.cellsig.2014.07.029","article-title":"Disordered hepcidin-ferroportin signaling promotes breast cancer growth","volume":"26","author":"Zhang","year":"2014","journal-title":"Cell Signal"},{"key":"10.1016\/j.kisu.2020.12.003_bib18","first-page":"9953","article-title":"Role of hepcidin and iron metabolism in the onset of prostate cancer","volume":"15","author":"Zhao","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.kisu.2020.12.003_bib19","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cmet.2008.09.012","article-title":"The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin","volume":"8","author":"Silvestri","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.kisu.2020.12.003_bib20","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2010-06-287292","article-title":"Suppression of hepatic hepcidin expression in response to acute iron deprivation is associated with an increase of matriptase-2 protein","volume":"117","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood-2007-07-100677","article-title":"Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis","volume":"111","author":"Silvestri","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib22","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib23","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2013-07-515957","article-title":"Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras\/RAF and nutrient-dependent mTOR signaling","volume":"123","author":"Mleczko-Sanecka","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.freeradbiomed.2018.07.020","article-title":"DMT1 and iron transport","volume":"133","author":"Yanatori","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.kisu.2020.12.003_bib25","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.kisu.2020.12.003_bib26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2018-05-815944","article-title":"Iron deficiency","volume":"133","author":"Camaschella","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib27","first-page":"9394060","article-title":"Limitations of serum ferritin in diagnosing iron deficiency in inflammatory conditions","volume":"2018","author":"Dignass","year":"2018","journal-title":"Int J Chronic Dis"},{"key":"10.1016\/j.kisu.2020.12.003_bib28","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ki.2009.21","article-title":"Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease","volume":"75","author":"Ashby","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF00241652","article-title":"Diurnal variations of serum erythropoietin in trained and untrained subjects","volume":"67","author":"Klausen","year":"1993","journal-title":"Eur J Appl Physiol Occup Physiol"},{"key":"10.1016\/j.kisu.2020.12.003_bib30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/1744-9987.12479","article-title":"Inter-method variability of ferritin and transferrin saturation measurement methods in patients on hemodialysis","volume":"21","author":"Kamei","year":"2017","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kisu.2020.12.003_bib31","doi-asserted-by":"crossref","first-page":"1606S","DOI":"10.3945\/ajcn.117.155887","article-title":"Laboratory methodologies for indicators of iron status: strengths, limitations, and analytical challenges","volume":"106","author":"Pfeiffer","year":"2017","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.kisu.2020.12.003_bib32","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1182\/blood-2006-11-057471","article-title":"Quantitation of hepcidin from human and mouse serum using liquid chromatography tandem mass spectrometry","volume":"110","author":"Murphy","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.12311","article-title":"Guideline for the laboratory diagnosis of functional iron deficiency","volume":"161","author":"Thomas","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kisu.2020.12.003_bib34","series-title":"Anaemia Management in Chronic Kidney Disease: Partial Update 2015","year":"2015"},{"key":"10.1016\/j.kisu.2020.12.003_bib35","series-title":"Assessing the Iron Status of Populations","article-title":"Indicators of the iron status of populations: ferritin","author":"Worwood","year":"2007"},{"issue":"suppl 1","key":"10.1016\/j.kisu.2020.12.003_bib36","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib37","doi-asserted-by":"crossref","first-page":"iii35","DOI":"10.1093\/ndt\/gfy175","article-title":"Chronic inflammation in end-stage renal disease and dialysis","volume":"33","author":"Cobo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib38","series-title":"Physiology, hepcidin. StatPearls. Treasure","author":"Chambers","year":"2020"},{"key":"10.1016\/j.kisu.2020.12.003_bib39","author":"Devkota"},{"key":"10.1016\/j.kisu.2020.12.003_bib40","series-title":"Assessing the Iron Status of Populations","article-title":"Indicators of the iron status of populations: free erythrocyte protoporphyrin and zinc protoporphyrin; serum and plasma iron, total iron binding capacity and transferrin saturation; and serum transferrin receptor","author":"Beard","year":"2007"},{"key":"10.1016\/j.kisu.2020.12.003_bib41","series-title":"Assessing the Iron Status of Populations","article-title":"The interpretation of indicators of iron status during an acute phase response","author":"Northrup-Clewes","year":"2007"},{"key":"10.1016\/j.kisu.2020.12.003_bib42","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ndt\/16.7.1416","article-title":"The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin","volume":"16","author":"Tessitore","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib43","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00467-018-3955-x","article-title":"Measurement of iron status in chronic kidney disease","volume":"34","author":"Hayes","year":"2019","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib44","first-page":"828","article-title":"Comparison between a novel latex immunoassay and LC-MS\/MS for hepcidin-25 measurement","volume":"30","author":"Kamei","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2215\/CJN.05931108","article-title":"Hepcidin--a potential novel biomarker for iron status in chronic kidney disease","volume":"4","author":"Zaritsky","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib46","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ndt\/gfp546","article-title":"Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate","volume":"25","author":"Peters","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib47","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/ndt\/gfr431","article-title":"Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study","volume":"27","author":"Uehata","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/1319-2442.256838","article-title":"Association of hepcidin and anemia in early chronic kidney disease","volume":"30","author":"Sonkar","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.kisu.2020.12.003_bib49","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/jcp.2003.015834","article-title":"How should stainable iron in bone marrow films be assessed?","volume":"57","author":"Hughes","year":"2004","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.kisu.2020.12.003_bib50","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation, and management of iron-restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0272-6386(95)90649-5","article-title":"Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era","volume":"26","author":"Kalantar-Zadeh","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2020.12.003_bib52","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2215\/CJN.04190510","article-title":"Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease","volume":"6","author":"Ferrari","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084144","article-title":"A\u00a03-marker index improves the identification of iron disorders in CKD anaemia","volume":"9","author":"Mercadal","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2020.12.003_bib54","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000253590","article-title":"Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in haemodialysis patients","volume":"122","author":"Costa","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1016\/j.kisu.2020.12.003_bib55","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11255-018-2062-z","article-title":"Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients","volume":"51","author":"El Sewefy","year":"2019","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib56","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1159\/000485865","article-title":"Serum hepcidin and iron indices affect anemia status differently according to the kidney function of non-dialysis chronic kidney disease patients: Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease (KNOW-CKD)","volume":"42","author":"Lee","year":"2017","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.kisu.2020.12.003_bib57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12882-017-0688-1","article-title":"Renal association clinical practice guideline on anaemia of chronic kidney disease","volume":"18","author":"Mikhail","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.299.6692.157","article-title":"Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously","volume":"299","author":"Macdougall","year":"1989","journal-title":"BMJ"},{"key":"10.1016\/j.kisu.2020.12.003_bib59","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kisu.2020.12.003_bib60","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","article-title":"FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia","volume":"29","author":"Macdougall","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib61","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","article-title":"A\u00a0randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD","volume":"68","author":"Van Wyck","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib62","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2020.12.003_bib63","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/ki.2015.163","article-title":"A\u00a0randomized trial of intravenous and oral iron in chronic kidney disease","volume":"88","author":"Agarwal","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib64","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1001\/jama.2015.15572","article-title":"Comparative risk of anaphylactic reactions associated with intravenous iron products","volume":"314","author":"Wang","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.kisu.2020.12.003_bib65","doi-asserted-by":"crossref","first-page":"f4822","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.kisu.2020.12.003_bib66","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int"},{"issue":"suppl 1","key":"10.1016\/j.kisu.2020.12.003_bib67","first-page":"S104","article-title":"Ferric pyrophosphate citrate as an iron replacement agent for patients receiving hemodialysis","volume":"21","author":"Fishbane","year":"2017","journal-title":"Hemodial Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157063","article-title":"Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: an analysis of the FIND-CKD Trial","volume":"11","author":"Gaillard","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2020.12.003_bib69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4103\/0971-4065.70840","article-title":"Iron status, inflammation and hepcidin in ESRD patients: the confounding role of intravenous iron therapy","volume":"20","author":"Jairam","year":"2010","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between\u00a0high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib71","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1681\/ASN.2005040423","article-title":"Time-dependent associations between iron and mortality in hemodialysis patients","volume":"16","author":"Kalantar-Zadeh","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib72","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib73","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A\u00a0novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD:\u00a0a\u00a028-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2020.12.003_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ckj\/sfy013","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease","volume":"12","author":"Holdstock","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2020.12.003_bib75","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib76","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ekir.2018.02.009","article-title":"An exploratory study of daprodustat in erythropoietin-hyporesponsive subjects","volume":"3","author":"Cizman","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.kisu.2020.12.003_bib77","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kisu.2020.12.003_bib78","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/1744-9987.12962","article-title":"A\u00a024-week anemia correction study of daprodustat in Japanese dialysis patients","volume":"24","author":"Tsubakihara","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kisu.2020.12.003_bib79","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1159\/000500232","article-title":"Outcomes of desidustat treatment in people with anemia and chronic kidney disease: a phase 2 study","volume":"49","author":"Parmar","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000496929","article-title":"A\u00a0placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial","volume":"49","author":"Akizawa","year":"2019","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib81","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2020.12.003_bib82","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib83","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib84","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2020.12.003_bib85","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib86","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib87","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib88","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/1744-9987.13468","article-title":"Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: results from two phase 3 studies","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.kisu.2020.12.003_bib89","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kisu.2020.12.003_bib90","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kisu.2020.12.003_bib91","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib92","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000464476","article-title":"Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease","volume":"45","author":"Martin","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib93","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/ndt\/gfy055","article-title":"Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents","volume":"34","author":"Haase","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kisu.2020.12.003_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.kisu.2020.12.003_bib95","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease","volume":"85","author":"Sheetz","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.kisu.2020.12.003_bib96","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1681\/ASN.2015040468","article-title":"Ergocalciferol supplementation in hemodialysis patients with vitamin D deficiency: a randomized clinical trial","volume":"27","author":"Miskulin","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12882-018-0823-7","article-title":"Effect of calcitriol on serum hepcidin in individuals with chronic kidney disease: a randomized controlled trial","volume":"19","author":"Panwar","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib98","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1073\/pnas.95.14.7987","article-title":"Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway","volume":"95","author":"Huang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.kisu.2020.12.003_bib99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.kisu.2020.12.002","article-title":"Hypoxia-inducible factor\u2013prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease","volume":"11","author":"Haase","year":"2021","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.kisu.2020.12.003_bib100","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1182\/blood-2004-05-1695","article-title":"HIF-2alpha regulates murine hematopoietic development in an erythropoietin-dependent manner","volume":"105","author":"Scortegagna","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib101","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kisu.2020.12.003_bib102","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1172\/JCI31370","article-title":"Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)","volume":"117","author":"Peyssonnaux","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kisu.2020.12.003_bib103","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ki.2009.460","article-title":"Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization","volume":"77","author":"Paliege","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.kisu.2020.12.003_bib104","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib105","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kisu.2020.12.003_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.kisu.2020.12.003_bib107","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.kisu.2020.12.003_bib112","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000502012","article-title":"Iron regulation by molidustat, a daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in patients with chronic kidney disease","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.kisu.2020.12.003_bib113","first-page":"823","article-title":"Randomized, open-label, active-controlled (darbepoetin alfa), phase 3 study of vadadustat for treating anemia in non-dialysis-dependent CKD patients in Japan","volume":"30","author":"Nangaku","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib114","first-page":"6","article-title":"Anemia and iron metabolism: clinical research randomized, double-blinded, active-controlled (darbepoetin alfa), phase 3 study of vadadustat in CKD patients with anemia on hemodialysis in Japan","volume":"30","author":"Nangaku","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3389\/fphar.2018.00803","article-title":"Correction of anemia in chronic kidney disease with Angelica sinensis polysaccharide via restoring EPO production and improving iron availability","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.kisu.2020.12.003_bib116","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/bph.13433","article-title":"Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects","volume":"173","author":"Boyce","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.kisu.2020.12.003_bib117","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/blood-2014-03-559484","article-title":"Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans","volume":"124","author":"van Eijk","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib118","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kisu.2020.12.003_bib119","doi-asserted-by":"crossref","first-page":"598","DOI":"10.3390\/molecules22040598","article-title":"Non-anticoagulant heparins are hepcidin antagonists for the treatment of Anemia","volume":"22","author":"Poli","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.kisu.2020.12.003_bib120","first-page":"20","article-title":"Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease","volume":"24","author":"Kim","year":"2014","journal-title":"J\u00a0Ren Nutr"},{"key":"10.1016\/j.kisu.2020.12.003_bib121","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1681\/ASN.2013040355","article-title":"Suppression of iron-regulatory hepcidin by vitamin D","volume":"25","author":"Bacchetta","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kisu.2020.12.003_bib122","doi-asserted-by":"crossref","first-page":"E389","DOI":"10.3390\/ijms19020389","article-title":"Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease","volume":"19","author":"Kaplan","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Kidney International Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2157171621000034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:54:22Z","timestamp":1761872062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171621000034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2157171621000034"],"URL":"https:\/\/doi.org\/10.1016\/j.kisu.2020.12.003","relation":{},"ISSN":["2157-1716"],"issn-type":[{"value":"2157-1716","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Iron metabolism and management: focus on chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Supplements","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kisu.2020.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}